Vitamin E Treatment in Tardive Dyskinesia

Abstract

Sixteen patients with tardive dyskinesia were treated with vitamin E in an open trial of on–off–on design. Abnormal involuntary movement scale (AIMS) ratings were performed in every phase of the study. The patients exhibited a significant reduction in their mean AIMS score during vitamin E treatment. Thus, this finding may suggest a possible role for vitamin E in the treatment of tardive dyskinesia. © 1997 John Wiley & Sons, Ltd.

Age-related susceptibility to chronic haloperidol-induced orofacial dyskinesia: Biochemical and neurochemical evidence

“…Several studies have indicated that orofacial dyskinesia increases with aging and the associated increased oxidative damage. [18][19][20] Cumulative free radical damage is connected with aging in the brain and it can further increase with chronic administration of neuroleptics such as haloperidol. [6] We initially studied the effect of aging on the different behavioral, biochemical, and neurochemical parameters in animals of different age-groups.…”

Age-related susceptibility to chronic haloperidol-induced orofacial dyskinesia: Biochemical and neurochemical evidence

“…Several studies have indicated that orofacial dyskinesia increases with aging and the associated increased oxidative damage. [18][19][20] Cumulative free radical damage is connected with aging in the brain and it can further increase with chronic administration of neuroleptics such as haloperidol. [6] We initially studied the effect of aging on the different behavioral, biochemical, and neurochemical parameters in animals of different age-groups.…”

Impact of Vitamins and Minerals Enriched Flora in the Management of Calciphytoliths: A Special Focus on Vitamin E

“…Parkinson's disease (3200 IU/day) [89]. the first stages of Huntington's disease (3000 IU/day) [90] and dyskinesia (800-160 IU/day) [91][92][93].…”

Vitamin E as a protective antioxidant in progressive renal failure

“…68 ) Vitamin E has been trialed in humans, with some success, in the treatment of diseases of the nervous system that involve oxygen‐free radicals and oxidative stress in their pathogenesis, including Friedreich’s ataxia (400 IU/day), 69 Alzheimer’s disease (2000 IU/day), 70 Parkinson’s disease (3200 IU/day), 71 the early stages of Huntington’s disease (3000 IU/day) 72 and tardive dyskinesia (800–1600 IU/day). 73–75 The optimal dose for vitamin E that may be helpful in slowing renal failure in humans may lie between 300 to 700 IU/day. (This is taken to be the safe ‘therapeutic range’, i.e.…”

Age-related susceptibility to chronic haloperidol-induced orofacial dyskinesia: Biochemical and neurochemical evidence

“…Several studies have indicated that orofacial dyskinesia increases with aging and the associated increased oxidative damage. [18][19][20] Cumulative free radical damage is connected with aging in the brain and it can further increase with chronic administration of neuroleptics such as haloperidol. [6] We initially studied the effect of aging on the different behavioral, biochemical, and neurochemical parameters in animals of different age-groups.…”

Impact of Vitamins and Minerals Enriched Flora in the Management of Calciphytoliths: A Special Focus on Vitamin E

“…Parkinson's disease (3200 IU/day) [89]. the first stages of Huntington's disease (3000 IU/day) [90] and dyskinesia (800-160 IU/day) [91][92][93].…”

Vitamin E as a protective antioxidant in progressive renal failure

“…68 ) Vitamin E has been trialed in humans, with some success, in the treatment of diseases of the nervous system that involve oxygen‐free radicals and oxidative stress in their pathogenesis, including Friedreich’s ataxia (400 IU/day), 69 Alzheimer’s disease (2000 IU/day), 70 Parkinson’s disease (3200 IU/day), 71 the early stages of Huntington’s disease (3000 IU/day) 72 and tardive dyskinesia (800–1600 IU/day). 73–75 The optimal dose for vitamin E that may be helpful in slowing renal failure in humans may lie between 300 to 700 IU/day. (This is taken to be the safe ‘therapeutic range’, i.e.…”

Age-related susceptibility to chronic haloperidol-induced orofacial dyskinesia: Biochemical and neurochemical evidence

“…Several studies have indicated that orofacial dyskinesia increases with aging and the associated increased oxidative damage. [18][19][20] Cumulative free radical damage is connected with aging in the brain and it can further increase with chronic administration of neuroleptics such as haloperidol. [6] We initially studied the effect of aging on the different behavioral, biochemical, and neurochemical parameters in animals of different age-groups.…”

Impact of Vitamins and Minerals Enriched Flora in the Management of Calciphytoliths: A Special Focus on Vitamin E

“…Parkinson's disease (3200 IU/day) [89]. the first stages of Huntington's disease (3000 IU/day) [90] and dyskinesia (800-160 IU/day) [91][92][93].…”

Vitamin E as a protective antioxidant in progressive renal failure

“…68 ) Vitamin E has been trialed in humans, with some success, in the treatment of diseases of the nervous system that involve oxygen‐free radicals and oxidative stress in their pathogenesis, including Friedreich’s ataxia (400 IU/day), 69 Alzheimer’s disease (2000 IU/day), 70 Parkinson’s disease (3200 IU/day), 71 the early stages of Huntington’s disease (3000 IU/day) 72 and tardive dyskinesia (800–1600 IU/day). 73–75 The optimal dose for vitamin E that may be helpful in slowing renal failure in humans may lie between 300 to 700 IU/day. (This is taken to be the safe ‘therapeutic range’, i.e.…”